Brief: Altamira Therapeutics To Develop Novel Generation Of Rheumatoid Arthritis Therapeutics Based On Its Proprietary Oligophore Delivery Platform And SiRNA Targeting Key Inflammation Checkpoint
25/07/2022 14:55
July 25 (Reuters) - Altamira Therapeutics Ltd CYTO.O :
* ALTAMIRA THERAPEUTICS TO DEVELOP NOVEL GENERATION OF
RHEUMATOID
ARTHRITIS THERAPEUTICS BASED ON ITS PROPRIETARY OLIGOPHORE
DELIVERY PLATFORM AND SIRNA TARGETING KEY INFLAMMATION
CHECKPOINT
Source text for Eikon: ID:nGNX5z30RC
Further company coverage: CYTO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Altamira Therapeutics
See all newsBrief: Altamira Therapeutics Reports Full Year 2024 Results
Brief: Altamira Therapeutics Announces Transition From Nasdaq To OTC Markets
Brief: Altamira Therapeutics Provides Update On Nasdaq Listing
Brief: Altamira Therapeutics Provides Business Update And First Half 2024 Financial Results
Brief: Altamira Therapeutics Announces Pricing Of Up To $12.0 Mln Public Offering